Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox ® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional Independent Evidence of ThermoDox’s Unique and Highly Effective Anti-Cancer Mechanism LAWRENCEVILLE, N.J , Jan.

Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data from a Phase I study of GEN-1, its DNA-based immunotherapy for the localized

Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc Analysis Subgroup Current Combined, Blinded Overall Survival (OS) Rate for Both Treat Arms is

Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic

ThermoDox® Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phase I/II OVATION 2 Study Enrolling Patients; First Look at Phase I Data Expected in First Quarter 2019 Company to Hold Conference Call on Thursday, November 15, 2018 at 11:00

LAWRENCEVILLE, N.J , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2018 and provide an update on its development programs for ThermoDox®, its

  Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol;  Patients in the Intent-to-Treat Population had a Median PFS of 17.1 months versus Historical Median PFS of 12 Months All Patients Treated at the Highest Dose Cohort Achieved

  Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development

LAWRENCEVILLE, N.J. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018 , the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the

  Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives LAWRENCEVILLE, N.J. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development